Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma

Starting soon · Not applicable

Conditions studied: Pancreatic Ductal Adenocarcinoma (mPDAC)

In brief

This case-control study aims to evaluate the role of a polygenic risk score in predicting the risk of pancreatic ductal adenocarcinoma (PDAC). The study will compare genetic risk profiles between individuals with PDAC and controls without the disease in order to assess whether a polygenic risk score may help identify individuals at higher risk. The findings may contribute to improving risk stratification and supporting future strategies for early identification and prevention of pancreatic cancer.

Key facts

Study ID

NCT07516392

Run by

Catholic University of the Sacred Heart

People needed

1140

Starts

2026-04-01

Expected to finish

2026-09-30

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults aged 18 years and older.
• Able and willing to provide informed consent.
• For cases: participants with pancreatic ductal adenocarcinoma.
• For controls: participants without pancreatic ductal adenocarcinoma.
• Availability of the clinical and/or biological data required for the study, including data necessary for polygenic risk score evaluation.

You may not qualify if…

• Age younger than 18 years.
• Inability to provide informed consent.
• Incomplete or unavailable clinical and/or biological data required for the study.
• Any condition that, in the judgment of the investigators, makes the participant unsuitable for inclusion

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.